Rita Nanda
Impact in
- Cancer Research top 0.1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
Papers in
-
- Breast Cancer Treatment Studies 85
- Cancer Genomics and Diagnostics 10
- Oncology 58
- Cancer Immunotherapy and Biomarkers 30
- HER2/EGFR in Cancer Research 14
- PARP inhibition in cancer therapy 6
- Co-authors
- Olufunmilayo Ibironke Olopade (25 shared papers)Charles M. Perou (4 shared papers)Maria Tretiakova (3 shared papers)Vassiliki Karantza (7 shared papers)Chad Livasy (1 shared paper)Dominic T. Moore (1 shared paper)Gamze Karaca (1 shared paper)Gursel Aktan (2 shared papers)
- Journals
- Breast Cancer Research and Treatment (19 papers)Journal of Clinical Oncology (18 papers)Annals of Oncology (15 papers)Clinical Cancer Research (13 papers)npj Breast Cancer (9 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Rita Nanda
167 papers receiving 15.2k citations
Rita Nanda's Hit Papers
Peers
Comparison fields: 5 of 117
- Cancer Research 6.9k
- Oncology 6k
- Pulmonary and Respiratory Medicine 1k
- Immunology 616
- Genetics 904
Countries citing papers authored by Rita Nanda
This map shows the geographic impact of Rita Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Nanda more than expected).
Fields of papers citing papers by Rita Nanda
This network shows the impact of papers produced by Rita Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Nanda. The network helps show where Rita Nanda may publish in the future.
Co-authors
The 25 scholars most cited alongside Rita Nanda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 183 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Hit paper breakdown → | 2020 | 1393 |
| 2 | Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study Hit paper breakdown → | 2016 | 1258 |
| 3 | The molecular portraits of breast tumors are conserved across microarray platforms Hit paper breakdown → | 2006 | 1119 |
| 4 | 2005 | 879 | |
| 5 | Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 681 |
| 6 | Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 663 |
| 7 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer Hit paper breakdown → | 2020 | 584 |
| 8 | Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 540 |
| 9 | Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer Hit paper breakdown → | 2016 | 475 |
| 10 | Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 401 |
| 11 | TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes Hit paper breakdown → | 2020 | 372 |
| 12 | Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients Hit paper breakdown → | 2021 | 319 |
| 13 | 2009 | 318 | |
| 14 | 2016 | 303 | |
| 15 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial Hit paper breakdown → | 2021 | 264 |
| 16 | 2020 | 250 | |
| 17 | 2013 | 234 | |
| 18 | 2005 | 218 | |
| 19 | 2006 | 211 | |
| 20 | 2021 | 206 |
About Rita Nanda
Rita Nanda is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pharmacology and Radiology, Nuclear Medicine and Imaging, having authored 183 papers that have together received 15.5k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (85 papers), Cancer Immunotherapy and Biomarkers (30 papers), HER2/EGFR in Cancer Research (14 papers), Advanced Breast Cancer Therapies (11 papers), Cancer Genomics and Diagnostics (10 papers), MRI in cancer diagnosis (10 papers), Pharmacogenetics and Drug Metabolism (7 papers) and PARP inhibition in cancer therapy (6 papers). The work is most often cited by research in Cancer Research (6.9k citations), Oncology (6k citations), Pulmonary and Respiratory Medicine (1k citations), Immunology (616 citations) and Genetics (904 citations). Rita Nanda has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Olufunmilayo Ibironke Olopade, Charles M. Perou, Maria Tretiakova, Vassiliki Karantza, Chad Livasy, Dominic T. Moore, Gamze Karaca, Gursel Aktan, Lajos Pusztai and Dezheng Huo. Their work appears in journals such as Breast Cancer Research and Treatment, Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research and npj Breast Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.